Endocalyx in Treatment Resistent Hypertension

Exclusion Criteria

• •1. Age \<18 years.
• •2. Estimated glomerular filtration rate (eGFR) \<20 ml/min/1.73m2 measured by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the 2012 cystatin C CKD-EPI formula.
• •3. A mean seated systolic blood pressure of at least 180 mmHg or a diastolic blood pressure of at least 110 mmHg.
• •4. Known secondary hypertension
• •5. An acute coronary syndrome, stroke, transient ischemic attack or cardiovascular surgery in the last 3 months.
• •6. Hospitalization for heart failure in the past 3 weeks.
• •7. Dialysis treatment or expected initiation of dialysis within 3 months of screening.
• •8. Women of child bearing potential who are not taking adequate contraception (i.e. \<1% failure rate).
• •9. Planned surgery in the next 12 weeks
• •10. Major surgery in the previous 4 weeks.
• •11. Use of prednisolone \>5 mg/day
• •12. Use of any other investigational drug.
• •13. Presence of significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy of less than 1 year.
• •14. A psychiatric, addictive or any disorder that compromises ability to give truly informed consent for participation in this study.
• •15. Known hypersensitivity to seaweed, corn, artichoke, grape, melon or to any of the excipients of Endocalyx.
• •16. Known hypersensitivity or allergies for milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat and soybeans.
• •17. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption.